Has Danielle Guminski received payments from drug or device companies?

Yes. Drug and device makers reported $2,990 in general payments to Danielle Guminski across 164 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Danielle Guminski did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Danielle Guminski come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Danielle Guminski

Psychiatric/Mental Health · Smithland, KYNPI 1932851219

Payments from drug & device makers

$2,990in general payments, 2019–2025

Across 164 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$512
Supernus Pharmaceuticals, Inc.$385
Vanda Pharmaceuticals Inc.$189
Axsome Therapeutics, Inc.$152
Alkermes, Inc.$123
plus $236 from 8 others

What the payments were for

Food & beverage$2,990100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	96	$1,393
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	27	$512
Supernus Pharmaceuticals, Inc.	7	$385
Vanda Pharmaceuticals Inc.	9	$189
Axsome Therapeutics, Inc.	7	$152
Alkermes, Inc.	6	$123
Lundbeck LLC	3	$62
Otsuka America Pharmaceutical, Inc.	2	$51
Corium, LLC	2	$45
Neurocrine Biosciences, Inc.	1	$17
E.r. Squibb & Sons, L.L.C.	1	$17
Collegium Pharmaceutical, Inc.	1	$16
Exact Sciences	1	$14
Sunovion Pharmaceuticals Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

QELBREE$276
VRAYLAR$250
CAPLYTA$116

How this compares

$2,990 in reported general payments places this provider in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VraylarCariprazine Hcl	114	$169,658
RexultiBrexpiprazole	17	$26,788
Risperdal ConstaRisperidone Microspheres	24	$20,519
VyvanseLisdexamfetamine Dimesylate	42	$16,449
QelbreeViloxazine Hcl	18	$12,316
AuvelityDextromethorphan Hbr/Bupropion	11	$11,725
Lisdexamfetamine Dimesylate	36	$7,856
Aripiprazole	52	$4,538
Methylphenidate ErMethylphenidate Hcl	32	$3,535
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	101	$2,781
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	44	$1,993
Quetiapine Fumarate	106	$1,126
Prazosin Hcl	108	$1,036
Mirtazapine	51	$974
Venlafaxine Hcl ErVenlafaxine Hcl	69	$625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieVraylar	$1,393	$169,658114 claims
Otsuka America Pharmaceutical, Inc.Rexulti	$51	$26,78817 claims
Supernus Pharmaceuticals, Inc.Qelbree	$385	$12,31618 claims
Axsome Therapeutics, Inc.Auvelity	$152	$11,72511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Smithland

Theresa WattsAshland$645K
Rachel ColeHopkinsville$503K
Denise de AngelisLouisville$384K
Jennifer SampangCrestview Hills$322K
Jeremy FisherSouth Shore$197K
Jessica EstesLewisport$175K
Christopher MulloneyNancy$95K
Davika MattoxMorehead$79K
Molly LutzCrestview Hills$71K
Hope SmithHopkinsville$68K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →